Logo

LabCorp to Develop Gene-Based Theranostic for ARCA Heart Failure Drug

Feb 13, 2007
NEW YORK (GenomeWeb News) — Laboratory Corporation of America today said it plans to develop a gene-based companion diagnostic to be paired with a cardiac drug ARCA Discovery is currently developing, the companies said today.
 
The test will identify genetic variations of the alpha-2c and the beta-1 adrenergic receptors, which appear to affect the way heart failure patients respond to the ARCA drug bucindolol.
 
Some variations of the receptors are associated with positive benefits in many patients, but other variants are associated with side effects, the companies said.
 
ARCA intends to seek approval for the drug along with the genetic test, which LabCorp will develop during the approval process.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.